Amgen places bet on heart drug as rivals go after sales

AMGEN INC. is developing a new anti-cholesterol medicine as its rivals chase after increased sales.
Posted 11/2/12

SAN FRANSISCO - Amgen Inc., the world’s largest biotechnology company, is developing a new anti-cholesterol medicine by 2015 that it sees as its best shot to offset reduced sales when its popular anemia drugs lose exclusivity.

Amgen, which has a facility in West Greenwich has traded at a record high by resorting to share buybacks and dividend payments, investor benefits that aren’t normally linked to biotech companies. By 2015, though, the anemia drugs Aranesp and Epogen, with a combined $4 billion in estimated sales this year, will face competition from rivals introducing cheaper follow-on versions, necessitating growth from new products.

The drug AMG-145 is one of several that companies are developing to target a cholesterol-regulating gene in the liver, a new approach to current therapies that generate $39 billion in annual sales. Some of the world’s biggest drugmakers, Pfizer Inc., Roche Holding AG and Sanofi are testing versions. Data to be presented next week at the American Heart Association meeting in Los Angeles will show how AMG-145 stacks up.

“It’s clear that the drug has blockbuster potential,” Michael Yee, an analyst with RBC Capital Markets in San Francisco, said in an interview. “AMG-145 could be a $500 million-plus opportunity for Amgen, and could be bigger depending on what parts of the market they capture.”

The market for drugs targeting the liver cholesterol gene may be at least $10 billion, said Adnan Butt, an analyst with RBC Capital Markets in San Francisco, in an e-mail. In the U.S. alone about 11 million patients aren’t keeping their cholesterol low enough with standard pills called statins, which include Pfizer’s Lipitor, and another 1 million can’t take them because of side effects such as muscle soreness, he said.

Product opening

That leaves an opening for Amgen’s AMG-145, which may head to pharmacies as soon as 2015 if study results confirm its efficacy, according to Yee. That may not be soon enough. New York-based Pfizer, the world’s biggest pharmaceutical company, Basel, Switzerland-based Roche, Sanofi, based in Paris, and its development partner on the drug, Tarrytown, New York-based Regeneron Pharmaceuticals Inc. are all racing to be first to sell their own inhibitors of the gene, called PCSK9, a status that can lead to market dominance.

Sanofi and Regeneron are testing their drug in the third of three clinical trials typically required for U.S. regulatory approval. Amgen said it will start its Phase 3 testing sometime next year.

Amgen fell less than 1 percent to $86.99 at 9:46 a.m. New York time. The company’s shares had gained 36 percent this year through yesterday.

“Neck and neck”

Amgen, Sanofi and Regeneron are running “neck and neck” to get Food and Drug Administration approval, said Steven Nissen, head of cardiology at Cleveland Clinic in Ohio. The class is eagerly awaited by physicians, he said.

“These drugs produce very substantial reductions in LDL cholesterol levels,” said Nissen, an unpaid consultant to Amgen on its PCSK9 inhibitor program, in a telephone interview. “It’s a big step in the right direction.”

For Amgen, winning the race is crucial. The medicine could become the first new blockbuster approved for the company since it unveiled its bone-strengthening drug, Xgeva, in November 2010. Another potentially top-selling product, the bone-growth therapy romosozumab, remains a few years away from approval as well, Christopher Raymond, an analyst with Robert Baird wrote in a September note that downgraded shares to neutral.

Next Page
PBN Hosted

Join PBN for the best networking event and party of the winter - January 15, 2015 - the Book of Lists Party at the Providence Public Library. Reserve your spot by December 31st and get a holiday gift from PBN!
  • Best Places to Work
    Enrollment is now open for the 7th annual Best Places to Work program. Winners w ...
  • Manufacturing Awards
    Applications are now being accepted for the 2nd Annual Manufacturing Awards. Dea ...
Purchase Data
Book of Lists
Book of Lists cover
PBN's annual Book of Lists has been an essential resource for the local business community for almost 30 years. The Book of Lists features a wealth of company rankings from a variety of fields and industries, including banking, health care, real estate, law, hospitality, education, not-for-profits, technology and many more.
Data icons
Data can be purchased as single lists, in either Excel or PDF format; the entire database of the published book, in Excel format; or a printed copy of the Book of Lists.
  • Purchase an e-File of a single list
  • Purchase an e-File of the entire Book of Lists database
  • Purchase a printed copy of the Book of Lists
    Latest News